Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sensus Healthcare, Inc. (SRTS) Beats Q4 Earnings and Revenue Estimates

10:55pm, Thursday, 10'th Feb 2022 Zacks Investment Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 128.57% and 18.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s
Accelerate Diagnostics (AXDX) slips 3% as 4Q revenue is expected to be ~$3.3M (consensus $3.75M) compared to $3.1M in 4Q20.FY21 revenue is expected to be $11.8M (consensus…
Insiders are buying these penny stocks during "tax loss season" The post Penny Stocks To Buy Now According To Insiders In December 2021 appeared first on Penny Stocks to Buy, Picks, News and Informati
Insiders are buying these penny stocks during "tax loss season" The post Penny Stocks To Buy Now According To Insiders In December 2021 appeared first on Penny Stocks to Buy, Picks, News and Informati
Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report released on Wednesday, Zacks.com reports. According to Zacks, Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, []
Nautilus Biotechnology (NASDAQ:NAUT) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership. Institutional & Insider Ownership 71.3% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, [] The post Contrasting Nautilus Biotechnology (NASDAQ:NAUT) and Accelerate Diagnostics (NASDAQ:AXDX) appeared first on ETF Daily News .
Goldman Sachs Group Inc. grew its position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 49.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 48,526 shares of the medical research companys stock after purchasing an additional 16,005 shares during the period. Goldman Sachs Group Inc. owned approximately []
Accelerate Diagnostics Inc. (NASDAQ:AXDX) concluded the trading at $4.97 on Friday, December 03 with a fall of -0.80% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $5.01 and 5Y monthly beta was reading 1.88 with its price kept floating in the Accelerate Diagnostics Inc.s (AXDX) -0.80% Retreat Justifies A Second Look Read More »
Brokerages expect that Accelerate Diagnostics, Inc. (NASDAQ:AXDX) will report earnings per share of ($0.34) for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Accelerate Diagnostics earnings. Accelerate Diagnostics reported earnings per share of ($0.33) during the same quarter last year, which suggests a negative year-over-year growth rate of 3%. The []
Accelerate Diagnostics Inc. (NASDAQ:AXDX) traded at $4.96 at close of the session on Monday, 11/29/21, made a downward move of -0.80% on its previous days price. Looking at the stock we see that its previous close was $5.00 and the beta (5Y monthly) reads 1.88. In terms of its 52-week price range, AXDX has a Accelerate Diagnostics Inc. (NASDAQ: AXDX) An Analysis Is What You Need Read More »
Charles Schwab Investment Management Inc. grew its stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 16.4% in the 2nd quarter, HoldingsChannel reports. The firm owned 236,347 shares of the medical research companys stock after acquiring an additional 33,349 shares during the quarter. Charles Schwab Investment Management Inc.s holdings in Accelerate Diagnostics were worth $1,905,000 []

Accelerate Diagnostics rallies on insider buying

07:59pm, Wednesday, 24'th Nov 2021 Seeking Alpha

Accelerate Pheno System Study Published In Clinical Infectious Diseases

12:39pm, Monday, 22'nd Nov 2021 Business Insider Markets
(RTTNews) - Accelerate Diagnostics Inc. (AXDX) announced the publication of its Improving Outcomes and Antibiotic Stewardship Study in the journal Clinical Infectious Diseases. The company noted that the multi-center, real-world study compared data before and after implementation of the Accelerate Pheno system across several hospitals to
Nuveen Asset Management LLC boosted its position in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 11.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 504,599 shares of the medical research companys stock after purchasing an additional 53,048 shares during the period. Nuveen Asset []
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE